New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
07:41 EDTBIIBBiogen says TECFIDERA effective in MS patients with high disease activity
New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis, as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec at the 66th American Academy of Neurology annual meeting in Philadelphia. A new post-hoc analysis from the Phase 3 studies, DEFINE and CONFIRM, reinforce that TECFIDERA can be effective in RRMS patients with high disease activity. In addition, new data from the Phase 4 MANAGE study show that gastrointestinal events experienced by patients in the clinical practice setting were mostly mild to moderate and generally manageable, and significantly decreased in prevalence within the first two months of TECFIDERA treatment. A post-hoc analysis of pooled data from the Phase 3 DEFINE and CONFIRM studies evaluated the efficacy of TECFIDERA in RRMS patients with highly active disease. The findings are consistent with the data from the overall intent-to-treat patient populations in DEFINE and CONFIRM, which supported the regulatory submissions for TECFIDERA globally. Results show that at two years, TECFIDERA taken twice daily significantly reduced annualized relapse rate by 60 percent and the proportion of patients who relapsed by 63 percent. There was no significant effect of TECFIDERA on 12-week confirmed disability progression.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:37 EDTBIIBBiogen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:19 EDTBIIBBiogen, Sobi report Phase 3 Alprolix paediatric study meets primary endpoint
Subscribe for More Information
07:10 EDTBIIBBiogen Idec, Swedish Orphan Biovitrum AB announce positive Alprolix results
Subscribe for More Information
February 26, 2015
08:15 EDTBIIBBiogen shares likely to continue to advance, says RBC Capital
Subscribe for More Information
February 25, 2015
06:14 EDTBIIBPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 19, 2015
18:25 EDTBIIBPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:08 EDTBIIBBiogen consortium identifies new ALS gene and signaling pathways
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use